Comparison of osteogenic differentiation induced by siNoggin and pBMP-2 delivered by lipopolysaccharide-amine nanopolymersomes and underlying molecular mechanisms
Huang M., Zhang X., Li J., Li Y., Wang Q., Teng W.
Animal Study, published in Int J Nanomedicine (2019) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Int J Nanomedicine (2019)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 31239677
- PMCID
- PMC6559258
- DOI
- 10.2147/ijn.s203540
- Citations
- 7
Abstract (original English)
Purpose: Gene therapies via Noggin small interfering (si)RNA ( siNoggin ) and bone morphogenetic protein ( BMP ) -2 plasmid DNA ( pBMP-2 ) may be promising strategies for bone repair/regeneration, but their ideal delivery vectors, efficacy difference, and underlying mechanisms have not been explored, so these issues were probed here. Methods: This study used lipopolysaccharide-amine nanopolymersomes (LNPs), an efficient cytosolic delivery vector developed by the research team, to mediate siNoggin and pBMP-2 to transfect MC3T3-E1 cells, respectively. The cytotoxicity, cell uptake, and gene knockdown efficiency of siNoggin -loaded LNPs (LNPs/ siNoggin ) were studied, then the osteogenic-differentiation efficacy of MC3T3-E1 cells treated by LNPs/ pBMP-2 and LNPs/ siNoggin , respectively, were compared by measuring the expression of osteogenesis-related genes and proteins, alkaline phosphatase (ALP) activity, and mineralization of the extracellular matrix at all osteogenic stages. Finally, the possible signaling pathways of the two treatments were explored. Results: LNPs delivered siNoggin into cells efficiently to silence 50% of Noggin expression without obvious cytotoxicity. LNPs/ siNoggin and LNPs/ pBMP-2 enhanced the osteogenic differentiation of MC3T3 E1 cells, but LNPs/ siNoggin was better than LNPs/ pBMP-2 . BMP/Mothers against decapentaplegic homolog (Smad) and glycogen syn
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.